Feedback
We’d love to hear your feedback on this activity. It helps us to continually improve our products.
CORRECT!
Faculty & Disclosures
Prof. Said Beydoun
Keck School of Medicine of USC, Los Angeles, CA, USA
Prof. Said R Beydoun is professor and division chief of neuromuscular medicine at the Department of Neurology at Keck Medicine of University of Southern California (USC), Los Angeles, CA, USA. Prof. Beydoun is also programme director of an ACGME-accredited Clinical Neurophysiology Fellowship. read more
As a principal investigator, Prof. Beydoun has participated in multiple research clinical trials. His clinical and research areas of expertise in the field of neuromuscular medicine include: amyotrophic lateral sclerosis (ALS), myasthenia gravis, peripheral neuropathy, chronic inflammatory demyelinating polyneuropathy , multifocal motor neuropathy and transthyretin amyloid neuropathy.
Prof. Beydoun has been published in several scientific journals on topics related to neuromuscular diseases. He is co-editor-in-chief of touchREVIEWS in Neurology. He is also an elected fellow of the American Academy of Neurology and a fellow of the American Association of Neuromuscular and Electrodiagnostic Medicine. Prof. Beydoun is a member of the medical/scientific advisory board of the Myasthenia Gravis Foundation of America and medical director of the Certified ALS Treatment Center of Excellence at Keck USC. He holds board certification by the American Board of Psychiatry and Neurology in Neurology, Clinical Neurophysiology, Neuromuscular Medicine and Pain Medicine.
Prof. Said Beydoun discloses: Advisory board fees Alexion Pharmaceuticals, Alnylam Pharmaceuticals, Amylyx Pharmaceuticals, Argenx, Biogen, Ionis Pharmaceuticals, Mitsubishi Tanabe Pharma, Octapharma, Takeda and UCB; Grants/research support from Abcuro, Amylyx Pharmaceuticals, Genentech, Healey MGH, Regeneron Pharmaceuticals, Sanofi and UCB; Speaker’s bureau fees from Alexion Pharmaceuticals, Alnylam Pharmaceuticals, Amylyx Pharmaceuticals, Argenx Pharmaceuticals, Grifols and Takeda.
Dr Pushpa Narayanaswami
Beth Israel Deaconess Medical Center, Boston, MA, USA
Dr Pushpa Narayanaswami is an associate professor of neurology at Harvard Medical School and vice-chair of clinical operations at the Department of Neurology, Beth Israel Deaconess Medical Center, Boston, MA. read more
In her clinical practice, Dr Narayanaswami manages neuromuscular conditions, with special emphasis on myasthenia gravis, myopathies and muscular dystrophies. Her advocacy work seeks to incorporate health services research with healthcare policy to improve patient care.
Dr Pushpa Narayanaswami is a fellow of the American Academy of Neurology. She is an associate editor for Muscle and Nerve, a member of the level of evidence team of Neurology and serves on the editorial board of Clinical Neuromuscular Disease. She is a member of the Board of Directors of the American Association of Neuromuscular and Electrodiagnostic Medicine, where she also chairs the Quality Improvement and Patient Safety Committee. She serves on the medical and scientific advisory board of the Myasthenia Gravis Foundation of America. She was part of the international panel that developed consensus guidelines for the management of myasthenia gravis.Â
Dr Pushpa Narayanaswami discloses: Advisory board fees from Alexion Pharmaceuticals, Argenx, Dianthus Therapeutics, Janssen and UCB; Consultancy fees from GSK; Grants/research fees from Alexion Pharmaceuticals; Financial support from Sanofi (relationship terminated); Stockholder in Momenta Pharmaceuticals, Pfizer and Viatris (relationship terminated).
Prof. Heinz Wiendl
Department of Neurology, University Hospital Münster, Münster, Germany
Prof. Heinz Wiendl is professor of neurology and chair of the Department of Neurology at the University Hospital of Münster in Germany. read more
Prof. Wiendl’s research focuses on inflammatory neurodegeneration and immune regulation and protection, as well as monitoring multiple sclerosis and its therapy. In 2017, he was appointed honorary professor at Sydney Medical School and in 2020, he received an honorary doctorate from the Medical Faculty of Mashhad, Iran.
Prof. Wiendl is a member of numerous scientific and academic advisory boards and expert panels, including editorial boards of international scientific journals in the fields of neurology, neurosciences and immunology.Â
Prof. Heinz Wiendl discloses: Advisory board fees from Alexion Pharmaceuticals, Argenx, Bristol Myers Squibb, Janssen, Merck, Novartis and Sandoz; Consultant fees from Actelion, Argenx, BD, Biogen, EMD Serono, Fondazione, Gossamer Bio, Idorsia, Immunic Therapeutics, Immunovant, Lundbeck, Merck, NexGen, Novartis, PSI CRO, Roche, Sanofi and UCB; Grants/research support from Alexion Pharmaceuticals, Amicus Therapeutics, Argenx, Biogen, CSL Behring, F. Hoffmann-La Roche, Genzyme, Merck, Novartis, Roche and UCB.
